Loading...
XNAS
MNKD
Market cap1.28bUSD
Jul 09, Last price  
4.14USD
1D
-2.59%
1Q
61.09%
Jan 2017
30.05%
IPO
-94.09%
Name

MannKind Corp

Chart & Performance

D1W1MN
XNAS:MNKD chart
P/E
218.16
P/S
3.67
EPS
0.02
Div Yield, %
—
Shrs. gr., 5y
7.13%
Rev. gr., 5y
39.89%
Revenues
349m
+22.23%
100,00010,00020,000093,00050,00035,000000174,758,00011,745,00027,859,00063,038,00065,144,00075,442,00099,770,000198,962,000285,504,000348,966,000
Net income
6m
-78.75%
-230,548,000-293,190,000-303,039,000-220,104,000-170,560,000-160,804,000-169,366,000-191,490,000-198,382,000-368,445,000125,664,000-117,333,000-86,975,000-51,903,000-57,240,000-80,926,000-87,400,000-11,938,00027,588,0005,863,000
CFO
18m
-57.06%
-189,794,000-245,146,000-271,288,000-184,083,000-148,654,000-123,837,000-119,860,000-128,732,0004,086,000-57,232,000-78,090,000-64,778,000-37,731,000-88,483,000-28,128,000-61,709,000-80,697,00034,094,00042,511,00018,255,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

MannKind Corporation operates as a biopharmaceutical firm, primarily focused on innovating and bringing to market respiratory-delivered treatments. Its efforts are directed towards tackling endocrine system disorders and rare lung conditions within the U.S. market. The company's key product is Afrezza, an inhaled insulin designed to improve glycemic control for adults managing diabetes. MannKind also actively markets Thyquidity, promoting it to adult and pediatric endocrinologists and other healthcare professionals for the treatment of hypothyroidism. In terms of collaborations, MannKind holds a strategic licensing and partnership agreement with United Therapeutics Corporation. Furthermore, it is collaborating with NRx Pharmaceuticals to develop a dry powder formulation of ZYESAMI (aviptadil), which is a synthetic variant of human vasoactive intestinal peptide intended to shield cells from inflammatory processes. Established in 1991, MannKind Corporation's corporate offices are located in Westlake Village, California.
URL
https://mannkindcorp.com/
IPO date
Jul 28, 2004
Employees
391
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT